15:33:22 EDT Thu 19 Jul 2018
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
CanniMed Therapeutics Inc
Symbol C : CMED
Shares Issued 24,433,412
Close 2018-01-12 C$ 24.03
Recent Sedar Documents

CanniMed files $725M lawsuit against Aurora, others

2018-01-12 18:56 ET - News Release

Mr. Brent Zettl reports

CANNIMED THERAPEUTICS INC. LAUNCHES $725 MILLION LAWSUIT ALLEGING MULTIPLE CLAIMS OF WRONGDOING RELATED TO AURORA HOSTILE BID

CanniMed Therapeutics Inc. filed a lawsuit today in the Ontario Superior Court of Justice, alleging breach of confidentiality, intentional interference with economic relations, conversion, breach of contract and other allegations pursuant to the Securities Act (Ontario). The lawsuit also alleges that Aurora Cannabis Inc., several large shareholders of CanniMed (Golden Opportunities Fund Inc., SaskWorks Venture Fund Inc., Apex Investment Limited Partnership and Vantage Asset Management Inc.), Westcap Mgt. Ltd., PFM Capital Inc., Canaccord Genuity Group Inc. and others participated in a civil conspiracy intended to injure the economic interests of CanniMed.

Additionally, CanniMed is seeking personal damages against one current and one former member of the CanniMed board, Doug Banzet and Robert Duguid, for their alleged involvement in the civil conspiracy and for breaching their fiduciary duties by failing to act in the best interests of CanniMed and its shareholders and instead acting out of self-interest and/or for the benefit of other corporations, for which they are also directors. Mr. Banzet is the chief financial officer of Golden Opportunities Fund and chief operating officer of Westcap Mgt. Mr. Duguid is founding partner of SaskWorks Venture Fund, partner at PFM Capital and vice-president, investments, at Apex Investment Fund.

The action (which has yet to be served) claims damages in the amount of $725-million resulting from the defendants' unlawful actions that have negatively affected the appreciation of the value of the common shares of CanniMed and prevented CanniMed from pursuing alternative change-of-control transactions for the benefit of CanniMed shareholders.

"Aurora knew, or should have known, that the information obtained and utilized to design and launch their hostile bid was obtained inappropriately. As a result of Aurora's use of this confidential information, CanniMed shareholders have been disadvantaged and deprived of seeing the full value of their shares. These bad actors, working in concert, have done the company and other shareholders a significant disservice, and we can't let them get away with this. I urge all shareholders not to tender to Aurora's hostile bid and to vote yes (green) for CanniMed's acquisition of the Newstrike Resources Ltd.," said Brent Zettl, president and chief executive officer, CanniMed.

Vote green. Do not tender.

The CanniMed board and management will vote their green proxies in support of CanniMed's acquisition of Newstrike Resources and will not tender to Aurora's bid. The board strongly recommends shareholders join them in doing the same, no matter how many shares are owned. Here's how:

  1. To vote for the Newstrike acquisition, vote green. Follow the instructions on the green VIF (voting instruction form) or form of proxy by Jan. 19, 2018, at 10 a.m. EST. Shareholders with questions or need help voting should contact Kingsdale Advisors by calling toll-free at 1-888-518-1554 or by e-mailing at contactus@kingsdaleadvisors.com.
  2. Ignore and recycle any blue proxy forms received.
  3. To reject Aurora's bid, simply do nothing. Do not tender your shares. If you have tendered your shares in error or now wish to withdraw, simply ask your broker or Kingsdale Advisors at 1-888-518-1554 or contactus@kingsdaleadvisors.com to assist with this process.

Shareholders are also encouraged to visit the Newstrike not Aurora website for more details.

About CanniMed Therapeutics Inc.

CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-(good manufacturing practices)-compliant production process, and world-class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

CanniMed, through its subsidiaries, was the first producer to be licensed under the Marijuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical cannabis system for 13 years, and has been producing safe and consistent medical cannabis for thousands of Canadian patients, with no incident of product diversion or recalls.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.